Trials / Completed
CompletedNCT03450343
Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Oral Azacitidine (CC-486) Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Medical University of South Carolina · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of adding oral azacitidine to the chemotherapy combination R-ICE. This study will also look at whether or not disease outcomes improve with the combination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oral azacitidine | Azacitidine can be taken with or without food at the same time every day. |
| DRUG | R-ICE | R-ICE is approved for the treatment of NHL before ASCT for relapsed or primary refractory diffuse large b-cell lymphoma. R-ICE consists of rituximab, etoposide, carboplatin and ifosfamide. R-ICE will be administered per institutional guidelines. |
Timeline
- Start date
- 2019-04-04
- Primary completion
- 2023-08-31
- Completion
- 2024-01-30
- First posted
- 2018-03-01
- Last updated
- 2024-10-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03450343. Inclusion in this directory is not an endorsement.